JYJing Yue

Jing Yue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Yue has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Jiaxin Xie

    Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    8 shared publications
  • Luyao Wang

    Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    8 shared publications
  • Shulin Yang

    Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    7 shared publications
  • Jiayun Chen

    Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    6 shared publications
  • Yifan Chu

    Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    6 shared publications
  • Yifan Chu

    Department of Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications

Latest Publications

  • Value of autoimmune screening and immunomodulatory treatment to improve subsequent pregnancy outcomes in patients undergoing preimplantation genetic testing

    by Luyao Wang, Jiayun Chen, Yifan Chu, Ying Zhang, Jing Yue, Wei Tu, Shulin Yang

    Introduction: We aimed to evaluate the clinical utility of autoimmune screening and the effectiveness of immunomodulatory treatment in preimplantation genetic testing (PGT) patients. Material and methods: In this retrospective cohort study, 151 PGT patients who experienced a failed first frozen embryo transfer (FET) were divided into two groups. Patients underwent immune marker screening before their second FET. Among them, 42 were classified into the immune-positive group and received targeted interventions, while 109 were categorized into the immune-negative group, which was further divided into an empirical medication subgroup (n = 43) and a no-intervention subgroup (n = 66). Baseline characteristics and pregnancy outcomes were analyzed using statistical methods, including univariate and multivariate logistic regression analyses. Results: We found that among PGT patients with first transfer failure, 28% (42/151) showed abnormal immune markers. Targeted therapy in immune-positive patients was associated with significantly improved clinical pregnancy rates compared to their first unscreened cycle (64.29% vs. 33.33%, p = 0.005), while reducing the miscarriage rate. In contrast, empirical immunomodulation in immune-negative patients did not provide any additional benefit in terms of live birth rate (39.53% vs. 43.94%, p = 0.649). Multivariate analysis confirmed that embryo quality was an independent positive predictor of both hCG positivity (p = 0.034) and clinical pregnancy (p = 0.022), whereas maternal age showed an inverse association with the likelihood of success (p < 0.05). Conclusions: Immune abnormalities are relatively prevalent in the PGT population. Targeted immunomodulatory interventions in immune-positive patients were associated with improved pregnancy outcomes. We recommend that these patients should undergo immune screening and targeted interventions before embryo transfer. However, empirical therapy in immune-negative individuals is unjustified.

  • Open Access

    Safety assessment of autologous ovarian tissue cryopreservation and transplantation in cancer patients: an updated review

    by Luyao Wang, Yifan Chu, Jiaxin Xie, Jiayun Chen, Yetan Liu, Shulin Yang, Ying Zhang, Jing Yue

    Recently, the global incidence of malignant tumors has been increasing with a notable trend toward younger patients, representing a major public health challenge. Fertility preservation has emerged as a key issue at the intersection of oncology and reproductive medicine. Ovarian tissue cryopreservation and transplantation (OTCT) offers a unique and valuable strategy, particularly for prepubertal girls and patients requiring immediate gonadotoxic therapy. Although OTCT can effectively restore ovarian endocrine function and fertility, its clinical application is largely limited by safety concerns, especially the potential risk of reintroducing viable malignant cells via transplanted ovarian tissue. Therefore, accurate detection of minimal residual disease (MRD) in cryopreserved ovarian tissue and effective tumor cell decontamination strategies are essential to ensure clinical safety. In addition, long-term follow-up data on the health status of offspring born after OTCT remain insufficient. This narrative review systematically summarizes the safety concerns of OTCT, focusing on cancer-specific ovarian tissue contamination risks, current MRD detection and purging techniques, as well as the intergenerational safety of offspring. Based on recent evidence, this review can further provide key conclusions and practical recommendations for the safety assessment of OTCT, with the aim of promoting the safe, standardized, and widespread clinical application of this technique.


  • Open Access

    The impact of previous history of malignant tumors/precancerous lesions on IVF/ICSI outcomes: a retrospective cohort study

    by Luyao Wang, Yifan Chu, Jiaxin Xie, Jiayun Chen, Yetan Liu, Shulin Yang, Peiwen Yang, Ying Xiao, Lei Jin, Ying Zhang, et al.

    The incidence of malignant tumors/precancerous lesions is rising, yet their impact on pregnancy outcomes in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) remains unclear. A single-center retrospective cohort study was conducted at the Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2015 and December 2022. Propensity score matching (PSM) was applied to match the baseline data of the two groups, and the primary outcome were the conservative/optimistic cumulative live birth rates (CLBR) across multiple cycles. A total of 1004 patients were enrolled, including 251 individuals in the malignant tumors/precancerous lesions group (363 oocyte retrieval cycles) and 753 PSM controls (895 oocyte retrieval cycles). Compared with the controls, patients with a history of malignant tumors/precancerous lesions exhibited significantly lower ovarian reserve and poorer embryo outcomes (all p < 0.05). Both conservative and optimistic CLBR were lower in the malignant tumors/precancerous lesions group across multiple cycles (p < 0.05). After multiple oocyte retrievals, the conservative CLBR for malignant tumors/precancerous lesions plateaued at around 53% after four cycles, while optimistic CLBR reached 70% after four cycles. Among patients with prior malignant tumors/precancerous lesions who completed follow-up, the overall recurrence rate after IVF/ICSI treatment was 7.03% with no adverse events. Patients with a previous history of malignant tumors/precancerous lesions demonstrated inferior live birth outcomes compared to controls. Multiple ovarian stimulations improved live birth opportunities without significantly increasing the risk of tumor recurrence.

  • Open Access

    Machine learning-based endometrial ultrasound radiomics habitat analysis for predicting pregnancy outcomes after embryo transfer

    by Jiaxin Xie, Zuhan Geng, Jiayun Chen, Shulin Yang, Yuke Xie, Yifan Chu, Luyao Wang, Yetan Liu, Ying Zhang, Jing Yue

    Predicting in vitro fertilization (IVF) pregnancy outcomes is crucial for individualized decision-making. However, due to complex interactions among multip


  • Open Access

    Impact of Latent Tuberculosis Infection on Ovarian Reserve and In Vitro Fertilization or Intracytoplasmic Sperm Injection Outcomes: A Retrospective Cohort Study with Propensity Score Matching

    by Yifan Chu, Jialiang Zhang, Luyao Wang, Jiaxin Xie, Jiayun Chen, Miao Yan, Xinyao Hu, Bo Zhang, Jing Yue

    Background: Tuberculosis is a communicable disease that is a major cause of ill health and one of the leading causes of death worldwide. Latent tuberculosis infection (LTBI) widely exists in people all over the world, especially in patients with unexplained infertility, and the relationship between latent tuberculosis infection and ovarian reserve, as well as pregnancy outcomes of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), remains poorly understood.


  • Open Access

    The mechanism and protective strategies of follicle injury after ovarian tissue cryopreservation and thawed transplantation: a review

    by Yifan Chu, Jialiang Zhang, Luyao Wang, Jiaxin Xie, Jiayun Chen, Xinyao Hu, Juepu Zhou, Ruolin Mao, Miao Yan, Jing Yue

    The incidence of early-onset malignancies in reproductive-aged women is rising, necessitating effective fertility preservation strategies. Ovarian tissue cryopreservation (OTC) remains the sole option for prepubertal girls and patients requiring urgent oncologic treatment. However, post-transplant follicular attrition—driven by ischemia-reperfusion injury, oxidative stress, and aberrant primordial follicle activation—remains a major barrier. This comprehensive review elucidates the multiscale mechanisms of cryopreservation-induced follicular damage and evaluates cutting-edge strategies, including antifreeze protein-engineered cryoprotectants, angiogenesis-modulating scaffolds, and mTOR pathway inhibition. By integrating recent advances in biomaterial science and cryobiology, this study provides actionable insights to enhance OTC clinical efficacy and advance reproductive medicine.


  • Open Access

    Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study

    by Luyao Wang, Jiaxin Xie, Yifan Chu, Jiayun Chen, Lei Jin, Jing Yue

    For poor ovarian response patients, obtaining higher number of transferable and high-quality embryos is crucial and progestin-primed ovarian stimulation protocol is becoming widespread and constantly improving in this population. Letrozole has shown promise in numerous protocols and individuals. This study aims to evaluate the effect of the early addition of letrozole in progestin-primed ovarian stimulation protocol among expected poor ovarian response patients. This retrospective cohort study was performed in POSEIDON group 3 and 4 patients who underwent in vitro fertilization or intracytoplasmic sperm injection with their first progestin-primed ovarian stimulation protocol from January 1, 2018 to December 31, 2021. Totally 557 patients were enrolled in this research with 189 ovarian stimulation cycles for POSEIDON group 3 patients and 368 ovarian stimulation cycles for POSEIDON group 4 patients. The primary outcome of this study was the cumulative live birth rate and cumulative clinical pregnancy rate, and the second outcomes included the laboratory outcomes and pregnancy outcomes, maternal and neonatal complications also were encompassed. In this study, progestin-primed ovarian stimulation protocol combined with letrozole (study group) was associated with a significantly higher number of oocytes for retrieval and maturation [3.0 (2.0, 5.0) vs. 2.0 (1.3, 4.0), P < 0.001; 3.0 (2.0, 5.0) vs. 2.0 (1.0, 3.8), P < 0.001] as well as 2PN embryos [2.0 (1.0, 3.0) vs. 2.0 (1.0, 3.0), P = 0.026] among POSEIDON group 4 patients. In POSEIDON group 3 patients, the letrozole cotreatment did not show an advantage in these indicators. There was no significant difference in both cumulative live birth rate and cumulative clinical pregnancy rate between the study and control group in POSEIDON group 3 and 4 patients. Multivariate logistic regression model showed that significant favorable effects of the number of available embryos on cumulative live birth rate in all included patients. These findings indicate that advanced-aged poor ovarian response patients may benefit more from using letrozole as an advantageous adjuvant agent in the progestin-primed ovarian stimulation protocol to obtain more oocytes and embryos in clinical practice. Trial registration This trial was retrospectively registered


  • Open Access

    Interprofessional teaching rounds in medical education: improving clinical problem-solving ability and interprofessional collaboration skills

    by Peiwen Yang, Ting Xiong, Xiyuan Dong, Shulin Yang, Jing Yue

    Interprofessional teaching rounds are a practical application of interprofessional education in bedside teaching, yet there is a lack of research on how interprofessional teaching rounds should be implemented into medical education. This study aimed to describe our experience in developing and implementing interprofessional teaching rounds during a clerkship rotation for medical students, and compares its strengths and weaknesses relative to traditional teaching rounds. Medical students were assigned to either the interprofessional teaching round group (n = 24) or the traditional teaching round group (n = 25), and each group participated in their assigned type of teaching round. A quiz including medical knowledge of gynecological and obstetric diseases was used to assess the students' diagnostic and treatment abilities after teaching rounds. Additionally, a survey was conducted among students to evaluate whether the interprofessional teaching rounds were helpful. The results showed that when using interprofessional teaching rounds, the test score for medical knowledge related to the diagnosis and treatment of gynecological and obstetric diseases was significantly higher than the traditional teaching round group (85.5 ± 11.2 vs 78.3 ± 12.5, p = 0.038). Additionally, the interprofessional teaching rounds significantly enhanced understanding of clinical application, identification, and appropriate problem-solving in cases, as well as examination of different disciplinary aspects of a case, and improvement of interdisciplinary collaboration skills compared to traditional teaching rounds. Our study demonstrates that interprofessional teaching rounds can serve as an effective teaching method for enhancing medical students' ability to collaborate interprofessionally and to solve clinical problems comprehensively.


  • A Compound Heterozygous Pathogenic Variant in ZP2 Gene Causes Female Infertility

    by Shulin Yang, Zongzhe Li, Xinling Ren, Jing Yue

    The oocyte maturation defect 6 is an autosomal recessive hereditary disease caused by a homozygous variant in ZP2 gene. It is characterized by female primary infertility due to an abnormally thin zona pellucida (ZP) and defective sperm binding. Here we identified a compound heterozygous variant (c.1924C > T and c.1695-2A > G) in ZP2 gene in a Chinese Han family. Quantitative real-time PCR showed that the variant c.1924C > T significantly decreased the expression of truncated ZP2 message RNA by the nonsense-mediated decay pathway. Minigene assays showed the c.1695-2A > G variant led to an extra—61—nt preservation of intron 15 at the junction between exons 15 and 16 during transcription. Both variants (c.1924C > T and c.1695-2A > G) resulted in truncated ZP2 proteins (p.R642X and p.C566Hfs*2) that lost the transmembrane domain, which prevented the secretion of the mutant ZP2 proteins and produced a structurally abnormal ZP, thus resulting in female infertility. This study further elucidated the pathogenic mechanism of these two variants and provided new support for the genetic diagnosis of female infertility.


  • Open Access

    Outcomes of fertility preservation before or after anticancer treatments in young breast cancer patients and survivors: a single-center retrospective study and clinical experiences

    by Luyao Wang, Yifan Chu, Jiaxin Xie, Shulin Yang, Jing Yue

    Background Fertility preservation (FP) is gradually becoming a crucial cure during fertility counseling for all breast cancer (BC) women of reproductive age, but certain limiting factors hinder patients' decisions. This study aimed to collect cases involving fertility preservation before anticancer treatments and assisted reproductive technology (ART) after anticancer therapies in young breast cancer (BC) patients and survivors and to share some clinical experiences. Methods We retrospectively analyzed 18 BC patients who underwent FP before (neo)adjuvant chemotherapy and 8 survivors who chose ART after completing anticancer treatments in a single reproductive medicine center between January 2015 and June 2023. Baseline characteristics and outcomes of FP and ART were analyzed. Results 8 survivors of a median age of 35.5 years (range 32.3–41.0 years) underwent ART after anticancer therapies and behaved diminished ovarian reserve (DOR) or even premature ovarian insufficiency (POI) with undesirable outcomes. Receiving FP before (neo)adjuvant chemotherapy in 18 patients does not delay subsequent treatments, patients receiving neoadjuvant chemotherapy tend to prefer RS-COS protocol that shorten the time from diagnosis to initiation of chemotherapy (median days 26.0 vs. 42.0, p = 0.002) compared to the majority of patients receiving cCOS protocol, and there is no difference in other FP results. COS with letrozole can control the serum estradiol level in a relatively safe condition. During a median follow-up period of 17.5 months (range 8.8–31.0 months), only 1 (5.6%) woman suffered recurrence with bone metastasis when she received neoadjuvant chemotherapy after FP, 2 (11.1%) patients experienced ovarian hyperstimulation syndrome (OHSS) after COS, and 3 (37.5%) survivors had a live birth after ART. Conclusions Embryo and oocyte cryopreservation after COS based on letrozole is a preferred and optimal FP option for young BC patients before (neo)adjuvant chemotherapy. Using ART to get pregnant in BC survivors is feasible and not associated with adverse cancer outcomes. It is important that these patients are closely monitored to reduce the potential risks of OHSS and recurrence.